Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Novo Nordisk Launches NovoFine Plus Needle

By Drug Discovery Trends Editor | January 20, 2014

Novo Nordisk is now launching NovoFine Plus 32G 4mm, an ultra-thin, ultra-short universal pen needle that aims to make injections more comfortable for patients with diabetes. Canada is the first country to make NovoFine Plus available and will be followed by several other countries during 2014 and 2015.  
 
NovoFine Plus is as thin as two human hairs and 4mm long, making it the shortest needle Novo Nordisk has ever made. Its thinness and length are associated with less pain and less risk of intramuscular injection.
 
Studies have shown that people with type 2 diabetes are often reluctant towards initiating insulin therapy, with needle anxiety cited as a common barrier to initiation. Therefore, good design and user-friendly features that take into account patient concerns, such as ease of use and comfort, are important.
 
As NovoFine Plus uses SuperFlow technology, it also offers patients faster injections that need less force. It is compatible with all major pen devices9 and has been designed to reduce the risk of bending or breakage.
 
“We know needle anxiety can be a real barrier when people with diabetes start insulin therapy, and in some people this fear really compromises their treatment. Novo Nordisk is committed to improving diabetes care and as part of our broad portfolio within treatment, devices and needles, we’re pleased to provide this new option to people with diabetes,” said Jesper Kløve, senior vice president, Device R&D, Novo Nordisk.
 
Date: January 20, 2014
Source: Novo Nordisk

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50